Table 4. Immunohistochemistry analysis for evaluable patients (N=36).
| POSITIVE | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| NEGATIVE | ER | PR | AR | HER2 | EGFR | HSP90 | HSP70 | PTEN | |
| ER | X | 0 | 10 | 9 | 14 | 15 | 4 | 5 | |
| PR | 8 | X | 16 | 16 | 14 | 21 | 5 | 7 | |
| AR | 3 | 1 | X | 7 | 8 | 9 | 2 | 3 | |
| HER2 | 3 | 2 | 8 | X | 12 | 9 | 4 | 5 | |
| EGFR | 12 | 5 | 13 | 16 | X | 15 | 2 | 4 | |
| HSP90 | 4 | 1 | 5 | 4 | 6 | X | 0 | 2 | |
| HSP70 | 12 | 5 | 17 | 18 | 12 | 27 | X | 7 | |
| PTEN | 10 | 4 | 14 | 16 | 11 | 18 | 4 | X | |
ER estrogen receptor, PR progesterone receptor, AR androgen receptor, HER2 human epidermal growth factor receptor 2, EGFR epidermal growth factor receptor 2, HSP90 heat shock protein 90, HSP70 heat shock protein 70, PTEN phosphatase and tensin homolog